Regenerative medicine company AVITA Therapeutics (ASX:AVH) has announced a preclinical research collaboration pairing its Spray-On Skin Cells with Houston Methodist Research Institute’s expertise in reversing cellular aging.
AVITA's technology platform enables point-of-care autologous skin restoration for multiple unmet needs.
The company said the project seeks to establish proof-of-concept for the development of a novel approach to reverse aging and rejuvenate skin, with the potential for broader applicability, such as scar revision and wound healing.
AVITA said it has also entered into an option agreement to negotiate an exclusive worldwide license to it technology for skin applications.
“The Houston Methodist Research Institute is at the forefront of developing cutting-edge approaches for reversing cellular aging, and we look forward to working together on the exploration of combining their technology with AVITA Therapeutics’ proprietary Spray-on Skin Cells to rejuvenate aging skin,” said Dr Mike Perry, CEO of AVITA Therapeutics.
“This collaboration expands our pipeline to include exploration of modified-cells delivery and is another milestone in our commitment to harnessing the promise of regenerative medicine and unlocking the full potential of our technology platform to improve patients’ lives through skin restoration.”
Under the agreement, AVITA will gain access to Houston Methodist’s innovative technologies, including an RNA-based approach to rejuvenate human cells.
AVITA Therapeutics and the Houston Methodist Research Institute will explore applications of this RNA technology to rejuvenate skin by reversing aging mechanisms.